C1S and hereditary angioedema: Treatment guidelines from the US Hereditary Angioedema Association (HAEA) advisory board also recognize that further advancements with novel long-term prophylactic treatment options for HAE (namely C1-esterase inhibitor SC [human], lanadelumab, and berotralstat) have led to a shift in the paradigm of care, with the ability to achieve the realistic treatment targets of reducing the frequency and severity of attacks [2].